Early treatment of benign prostatic hyperplasia: Implications for reducing the risk of permanent bladder damage

Drugs and Aging

Volumn 20, Issue 3, 2003, Pages 185-195

  Tubaro, Andrea ^a,c   Carter, Simon ^b   Trucchi, Alberto ^a   Punzo, Giorgio ^a   Petta, Stefano ^a   Miano, Lucio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CHARING CROSS HOSPITAL   (United Kingdom)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; DOXAZOSIN; FINASTERIDE; INDORAMIN; PRAZOSIN; TAMSULOSIN;

AGED; AGING; BLADDER; BLADDER NECK STENOSIS; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COHORT ANALYSIS; COST BENEFIT ANALYSIS; DEATH; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; PROSTATE SURGERY; PROSTATISM; QUALITY OF LIFE; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; SYMPTOMATOLOGY; URETHRA; URINE RETENTION;

HUMANS; MALE; PROSTATIC HYPERPLASIA; URINARY BLADDER; URINARY BLADDER DISEASES;

EID: 0345118200     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200320030-00003     Document Type: Review

References (91)

1. Abrams P, Bruskewitz R, de la Rosette J, et al. The diagnosis of bladder outlet obstruction: urodynamics. In: Cockett ATK, Khoury S, Aso Y, et al., editors. Proceedings from the 3rd International Consultation on BPH; Jersey, Channel Islands: Scientific Communication International Ltd., 1996: 297-367
2. Hald T. Urodynamics in benign prostatic hyperplasia: a survey. Prostate Suppl 1989; 2: 69-77
3. Tubaro A, Carter S, Hind A. et al. A prospective study of the safety and efficacy of suprapubic transvesical prostatectomy in patients with benign prostatic hyperplasia. J Urol 2001; 166: 172-6
4. Boyle P, Maisonneuve P, Steg A. Decrease in mortality from benign prostatic hyperplasia: a major unheralded health triumph. J Urol 1996; 155: 176-80
5. Lu-Yao GL, Barry MJ, Chang C-H, et al. Prostate Outcome Research Team. Transurethral resection of the prostate among Medicare beneficiaries in the United States: time, trends and outcomes. Urology 1994; 44: 692-8
6. Tubaro A, Montanari E. Management of symptomatic BPH in Italy: who is treated and why? Eur Urol 1999; 39 Suppl. 3: 28-32
7. Tubaro A, de la Rosette J, Höfner K, et al. Correlations amongst objective and subjective parameters of bladder outlet obstruction in the clinical response to microwave thermotherapy. Urodinamica 1998; 8: 200-10
8. Jardin A, Andersson K-E, Chapple C, et al. α 1-Adrenoceptor antagonists in the treatment of BPH. In: Chatelain C, Denis L, Foo KT, et al., editors. Benign prostatic hyperplasia. Plymouth (UK): Health Publication, 2002: 459-78
9. Caine M, Pfau A, Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 1976; 48 (4): 255-63
10. Abrams PH, Shah PJR, Stone AR, et al. Bladder outflow obstruction treated with phenoxybenzamine. Prog Clin Biol Res 1981; 78: 269-75
11. Thien T, Delaere KP, Debruyne FM, et al. Urinary incontinence caused by prazosin. Br J Med 1978; 2: 622-3
12. Kirby RS, Coppinger SWC, Corcoran MO, et al. Prazosin in the treatment of prostatic obstruction: a placebo-controlled study. Br J Urol 1987; 50: 136-42
13. Imperato-McGinley J, Guerrero L, Gautier T, et al. Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974; 186: 1213-5
14. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in man with benign prostatic hyperplasia. N Engl J Med 1992; 327: 1185-91
15. Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993; 22: 291-9
16. Jardin A, Bensadoun H, Delauche-Cavallier MC, et al. Alfuzosin for the treatment of benign prostatic hypertrophy. Lancet 1991; 337: 1457-61
17. Lepor H, Auerbach S, Puras-Baez A, et al. A randomized, placebo-controlled, multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992; 148: 1467-74
18. Fawzy A, Braun K, Lewis GP, et al. for the Multicenter Study Group. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995; 154: 105-9
19. Abrams P, Schulman CC, Vaage S, et al. Tamsulosin, a selective α1c-adrenoceptor antagonist: a randomised, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). Br J Urol 1995; 76: 325-36
20. Moore E, Bracken B, Bremner W, et al. Proscar: five-year experience [published in erratum appears in Eur Urol 1996; 29 (2): 234]. Eur Urol 1995; 28: 304-9
21. Bruskewitz R, Girma CJ, Fowler J, et al. Effect of finasteride on bother and other health related quality of life aspects associated with benign prostatic hyperplasia. Proscar Long-term Efficacy Safety Study Group. Urology 1999; 54: 670-8
22. Jardin A, Bensadoun H, Delauche-Cavallier MC, et al. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group. Br J Urol 1993; 72: 615-20
23. Fawzy A, Hendry A, Cook E, et al. Long-term (4 year) efficacy and tolerability of doxazosin for the treatment of concurrent benign prostatic hyperplasia and hypertension. J Urol 1999; 6: 346-54
24. Lepor H. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. Urology 1995 Mar; 45 (3): 406-13
25. Debruyne FM, Witjes WP, Fitzpatrick J, et al. The international terazosin trial: a multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. The ITT Group. Eur Urol 1996; 30 (3): 369-76
26. Lukacs B, Grange JC, Comet D, et al. Prospective follow-up of 3,228 patients suffering from clinical benign prostatic hyperplasia (BPH) treated for 3 years with alfuzosin in general practice. BPH Group in General Practice Prog Urol 1999; 9: 271-80
27. Schulman CC, Lock TMTW, Buzelin JM, et al. the European Tamsulosin Study Group. Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. J Urol 2001; 166: 1358-63
28. Chapple CR. Alpha blockade, In: Chapple CR, McConnell JD, Tubaro A, editors. Benign prostatic hyperplasia. Current therapy. London: Martin Dunitz, 2000: 1-26
29. Tammela T. 5α-reductase inhibitors. In: Chapple CR, McConnell JD, Tubaro A, editors. Benign prostatic hyperplasia. Current therapy, London: Martin Dunitz, 2000: 27-37
30. Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997; 158: 481-7
31. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998; 338: 557-63
32. Flanigan RC, Reda DJ, Wasson JH, et al. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol 1998; 160 (1): 12-6; discussion 16-7
33. Lee AJ, Russel EB, Garraway WM, et al. Three-year follow-up of a community-based cohort of men with untreated benign prostatic enlargement. Eur Urol 1996; 30: 11-7
34. Rhodes T, Girman CJ, Jacobsen SJ, et al. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol 1999; 161: 1174-9
35. Sarma AV, Jacobsen SJ, Girman CJ, et al. Concomitatnt longitudinal changes in frequency of and bother from lower urinary tract symptoms in community dwelling men. J Urol 2002; 168 (4 Pt 1): 1446-52
36. Kaplan SA, Te AE, Pressler LB, et al. Transition zone index as a method of assessing benign prostatic hyperplasia: correlation with symptoms, urine flow and detrusor pressure. J Urol 1995 Nov; 154 (5): 1764-9
37. Bosch JL, Hop WC, Kirkels WJ, et al. The International Prostate Symptom Score in a community-based sample of men between 55 and 74 years of age: prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. Br J Urol 1995 May; 75 (5): 622-30
38. Lepor H, Nieder A, Feser J, et al. Total prostate and transition zone volumes, and transistion zone index are poorly correlated with objective measures of clinical benign prostatic hyperplasia. J Urol 1997; 158 (1): 85-8
39. Wei JT, Schottenfeld D, Cooper K, et al. The natural history of lower urinary tract symptoms in black American men: relationships with aging, prostate size, flow rate and bothersomeness. J Urol 2001; 165 (5): 1521-5
40. Witjes WP, Aarnink RG, Ezz-el-Din K, et al. The correlation between prostate volume, transition zone volume, transition zone index and clinical and urodynamic investigations in patients with lower urinary tract symptoms. Br J Urol 1997; 80 (1): 84-90
41. Sciarra A, D'Eramo G, Casale P, et al. Relationship among symptom score, prostate volume, and urinary flow rates in 543 patients with and without benign prostatic hyperplasia. Prostate 1998; 34 (2): 121-8
42. Roberts RO, Jacobsen SJ, Jacobsen DJ, et al. Longitudinal changes in peak urinary flow rates in a community-based cohort. J Urol 2000; 163: 107-13
43. Barry JM, Fowler Jr FJ, Bin L, et al. The natural history of patients with benign prostatic hyperplasia as diagnosed by the north American urologists. J Urol 1997; 157: 10-5
44. Fowler Jr FJ, Wennberg JE, Timothy RP, et al. Symptom status and quality of life following prostatectomy. JAMA 1988; 259: 3018-22
45. Mebust WK, Holtgrewe HL, Cockett ATK, et al. Transurethral prostatectomy, and postoperative complications: a cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 1989; 141: 243
46. Emberton M, Neal DE, Black N, et al. The National Prostatectomy Audit: the clinical management of patients during hospital admission. Br J Urol 1995; 75: 301-16
47. Roehrborn CG, Malice MP, Cook TJ, et al. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 2001; 58: 210-6
48. Roehrborn CG, McConnell JD, Lieber M, et al. Serum prostate-specific antigen concentrationis a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology 1999; 53 (3): 473-80
49. Nielsen KK. Changes in morphology, function and blood flow in mini-pig urinary bladder after chronic outflow obstruction and recovery from obstruction. Scand J Urol Nephrol 1997; 195 Suppl. 1: 1-39
50. Schröder A, Chichester P, Kogan BA, et al. Effect of chronic bladder outlet obstruction on blood flow of the rabbit bladder. J Urol 2001; 165: 640-6
51. Uvelius B, Mattiasson A. Detrusor collagen content in the denervated rat urinary bladder. J Urol 1986; 136: 1110-2
52. Malkowicz SB, Wein AJ, Elbadawi A, et al. Acute biochemical and functional alterations in the partially obstructed rabbit urinary bladder. J Urol 1986; 136: 1324-9
53. Gosling JA, Kung LS, Dixon JS, et al. Correlation between the structure and function of the rabbit urinary bladder following partial outlet obstruction. J Urol 2000; 163 (4): 1349-56
54. Schoor RA, Canning DA, Bella RD, et al. Ultrasound diagnosis of bladder outlet obstruction in rabbits. Neurourol Urodyn 1994; 13: 559-69
55. Kojima M, Inui E, Ochiai A, et al. Noninvasive quantitative estimation of infravesical obstruction using ultrasonic measurement of bladder weight. J Urol 1997; 157: 476-9
56. Manieri C, Carter S, Romano G, et al. The diagnosis of bladder outlet obstruction in men by ultrasound measurement of bladder wall thickness. J Urol 1998; 159: 761-5
57. Laniado ME, Patel A, Tubaro A, et al. Bladder wall thickness and free flow rate in a logistic regression predict patients who do not have lower urinary tract obstruction on pressure/flow urodynamic studies. J Urol 2001; 166 (6): 2221-5
58. Speakman MJ, Brading AF, Gilpin CJ, et al. Bladder outlet obstruction - a cause of denervation supersensitivity. J Urol 1987; 138: 1461-6
59. Brent L, Stephens FD. The response of smooth muscle cells in the urinary bladder to outflow obstruction. Invest Urol 1975; 12: 494-502
60. Mattiasson A, Uvelius B. Changes in contractile properties in hypertrophic rat urinary bladder. J Urol 1982; 128: 1340-2
61. Mostwin JL, Karin OM, van Koeveringe G, et al. The guinea pig as a model for gradual urethral obstruction. J Urol 1991; 145: 854-8
62. Gosling JA, Dixon JS. Structure of trabeculated detrusor muscle in cases of prostatic hypertrophy. Urol Int 1980; 35: 351-5
63. Ghoneim GM, Regnier CH, Biancani P, et al. Effect of vesical outlet obstruction on detrusor contractility and passive properties in rabbits. J Urol 1986; 135: 1284-9
64. Dixon JS, Gilpin CJ, Gilpin SA, et al. Sequential morphological changes in the pig detrusor in response to chronic partial urethral obstruction. Br J Urol 1989; 64: 385-90
65. Elbadawi A, Yalla SA, Resnik NM. Structural basis of geriatric voiding dysfunction. IV. Bladder outlet obstruction. J Urol 1993c; 150: 1681-95
66. Murakumo M, Ushiki T, Abe K, et al. Three-dimensional arrangement of collagen and elastin fibers in the human urinary bladder: a scanning electron microscopy study. J Urol 1995; 154 (1): 251-6
67. Uvelius B, Persson L, Mattiasson A. Smooth muscle cell hypertrophy and hyperplasia in the rat detrusor after short-time infravesical outflow obstruction. J Urol 1984; 131: 173-6
68. Kim KM, Kogan BA, Massad CA, et al. Collagen and elastin in the obstructed fetal bladder. J Urol 1991; 146: 528-31
69. Low RB, Stirewalt WS, Hultgren P, et al. Changes in collagen and elastin in rabbit right ventricular pressure overload. Biochem J 1989; 263: 709-13
70. Yokoyama O, Kawaguchi K, Hisazumi H. Denervation super-sensitivity of the detrusor muscle due to bladder overdistension, with special reference to the relationship between supersensitivity, and changes in the connective tissue. Hinyokika Kiyo 1985; 31: 2127-34
71. Sibley GN. The physiological response of the detrusor muscle to experimental bladder outflow obstruction in the pig. Br J Urol 1987; 60: 332-6
72. Speakman MJ, Brading AF, Gilpin CJ, et al. Bladder outflow obstruction - a cause of denervation supersensitivity. J Urol 1987 Dec; 138 (6): 1461-6
73. Speakman MJ, Brading AF, Dixon JS, et al. Cystometric, physiological and morphological studies after relief of bladder outflow obstruction in the pig. Br J Urol 1991; 68 (3): 243-7
74. Haugaard N, Potter L, Wein AJ, et al. Effect of partial obstruction of the rabbit urinary bladder on malate dehydrogenase and citrate synthase activity. J Urol 1992; 147 (5): 1391-3
75. Levin RM, Nicholas TJ, Snitkoff GG, et al. Subcellular distribution of SERCA and calcium-activated ATPase in rabbit and human urinary bladder smooth muscle. Pharmacology 1997; 55 (3): 136-43
76. Levin RM, Saito M, Wein AJ, et al. Effect of partial outlet obstruction on choline acetyltransferase activity in the rat and rabbit. Neurourol Urodyn 1993; 12 (3): 255-61
77. Brading AF, Turner WH. The unstable bladder: towards a common mechanism. Br J Urol 1994; 73: 3-8
78. Zhao Y, Levin SS, Wein AJ, et al. Correlation of ischemia/reperfusion or partial outlet obstruction-induced spectrin proteolysis by calpain with contractile dysfunction in rabbit bladder. Urology 1997; 49 (2): 293-300
79. Kato K, Lin AT, Haugaard N, et al. Effects of outlet obstruction on glucose metabolism of the rabbit urinary bladder. J Urol 1990; 143 (4): 844-7
80. Levin RM, Zderic SA, Yoon JY, et al. Effect of ryanodine on the contractile response of the normal and hypertrophied rabbit urinary bladder to field stimulation. Pharmacology 1993; 47 (4): 244-51
81. Wasson JH, Reda DJ, Bruskewitz RC, et al. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med 1995; 332: 75-9
82. Barry JM, Beckley S, Boyle P, et al. Epidemiology and natural history of BPH. In: Cockett ATK, Aso Y, Denis LJ, et al., editors. Proceedings from the 3rd International Consultation on BPH; Jersey, Channel Islands: Scientific Communication International Ltd., 1996: 21-36
83. Pickard R, Emberton M, Neal DE. The management of men with acute urinary retention. National Prostatectomy Audit Steering Group. Br J Urol 1998; 81 (5): 712-20
84. McConnell JD, for the MTOPS Steering Committee. The long term effects of medical therapy on the progression of LUTS: results from the MTOPS trial. J Urol 2002; 167 (4): 1042
85. Michel MC, Goepel M. Lower urinary tract symptoms suggestive of benign prostatic obstruction: what's the long term effectiveness of medical therapies? Eur Urol 2001; 39 Suppl. 3: 20-5
86. Michel MC, Goepel M. Treatment satisfaction of patients with lower urinary tract symptoms: randomised controlled trials vs. real life practice. Eur Urol 2000; 38 Suppl. 1: 40-7
87. Tubaro A, Vicentini C, Renzetti R, et al. Invasive and minimally invasive treatment modalities for lower urinary tract symptoms: what are the relevant differences in randomised clinical trials? Eur Urol 2000; 38 Suppl. 1: 7-17
88. Clifford GM, Logie J, Farmer RDT. How do symptoms indicative of BPH progress in real life practice?. The UK experience. Eur Urol 2000; 38 Suppl. 1: 48-53
89. Stoevelaar HJ, McDonnell J. Changing therapeutic regimens in benign prostatic hyperplasia: clinical and economic considerations. Pharmacoeconomics 2001; 19 (2): 131-53
90. Chapple CR. Alpha blockade. In: Chapple CR, McConnell JD, Tubaro A, editors. Benign prostatic hyperplasia. London: Martin Dunitz, 2000: 1-26
91. Ockrim JL, Laniado ME, Patel A, et al. A probability based system for combining simple office parameters as a predictor of bladder outflow obstruction. J Urol 2001 Dec; 166 (6): 2221-5